check_circleStudy Completed

Neoplasms

Bayer Identifier:

12874

ClinicalTrials.gov Identifier:

NCT01411410

EudraCT Number:

Not Available

EU CT Number:

Not Available
Phase I study of PI3(phosphoinositol 3)-Kinase inhibitor BAY80-6946 with paclitaxel in patients with advanced cancer

Trial purpose

This open label Phase 1 study involves treating subjects with advanced cancer with BAY80-6946 in combination with paclitaxel. It will determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of BAY80-6946 in combination with paclitaxel. The trial will involve multiple participating sites from the US. Following determination of the MTD, an expansion cohort of 20 evaluable subjects with breast cancer was planned. Finally, 16 patients have been enrolled to treatment (Cohort 3). A new expansion cohort with modified dosing cohort is now introduced (Cohort 4: breast cancer expansion cohort with modified dosing) in which another 20 subjects are planned to be enrolled to treatment.

Key Participants Requirements

Sex

Both

Age

18 - N/A
  • - Subjects must have defined tumor classification (ie, TNBC, HER2+ or Luminal) for enrollment. If tumor classification is not available the subject cannot be enrolled. Tumor classification can be based on analysis of archived tumor tissue, or analysis of tumor tissue collected at any time proximal to screening. Subject profile can also be derived from analysis of fresh tumor tissue obtained during screening. Shipment of specimens (archival or fresh tumor tissue, blood, and plasma) to a central lab can take place after subject enrollment.
    - No prior paclitaxel treatment for subjects in the dose escalation phase. MTD cohort expansion subjects may have had prior paclitaxel, but must not have experienced moderate or severe hypersensitivity reactions to the drug. Peripheral neuropathy must be Grade ≤ 1.
    - Histological or cytological documentation of non-hematologic malignant solid tumor, excluding primary brain or spinal tumors. Patients with prior central nervous system metastases are eligible if all of the following apply:  -- Definitive treatment for all lesions (eg, surgery, radiation) was completed at least three months prior to enrollment  -- All lesions must be stable or improving on MRI scan performed within one month of enrollment  -- All symptoms of the prior CNS metastases are stable.
    - At least one measurable lesion or evaluable disease, as per RECIST 1.1
    - ECOG Performance Status Assessment of 0 or 1
    - Life expectancy of at least 12 weeks
  • - History of moderate to severe hypersensitivity (allergy) to drugs formulated in Cremophor® EL (polyoxyethylated castor oil), such as vitamin K, cyclosporin for injection concentrate and teniposide for injection concentrate
    - Pre-existing interstitial lung disease and/or severe impaired pulmonary function
    - History of cardiac disease; congestive heart failure (CHF) >NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina, or ventricular cardiac arrhythmias requiring anti-arrhythmic therapy
    - Prior diagnosis of Type 1 or 2 diabetes mellitus, hyperglycemia (defined as consistent fasting blood or plasma glucose > 125 mg/dL) or HgBA1c ≥ 7%
    - Active clinically serious infections Grade ≥ 2 (NCI-CTCAE version 4.0), including viral hepatitis
    - Poorly controlled seizure disorder
    - Poorly controlled hypertension, defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
    - Known human immunodeficiency virus (HIV) infection or chronic hepatitis C or B
    - Subjects undergoing renal dialysis
    - Known bleeding diathesis
    - Pregnant or breast feeding women.

Trial summary

Enrollment Goal
55
Trial Dates
August 2011 - June 2015
Phase
Phase 1
Could I Receive a placebo
No
Products
Aliqopa (Copanlisib, BAY80-6946)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
St. Louis, 63110, United States
Terminated
New York, 10065, United States
Completed
Houston, 77030, United States

Primary Outcome

  • Adverse event collection
    date_rangeTime Frame:
    Up to 3 years or longer if indicated
    enhanced_encryption
    Safety Issue:
    Yes
  • Maximum tolerated dose, measured by adverse event profile
    date_rangeTime Frame:
    Up to 3 years or longer if indicated
    enhanced_encryption
    Safety Issue:
    Yes
  • Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed)
    Cmax: maximum drug concentration in plasma after single dose administration
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed)
    Cmax/D: Cmax divided by total dose in [mg]
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed)
    tmax: time to reach maximum drug concentration in plasma after single (first) dose
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed)
    AUC(0-tlast): AUC from time 0 to the last data point above lower limit of quantification
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed)
    AUC: area under the plasma concentration vs time curve from zero to infinity
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed)
    AUC/D: AUC divided by total dose in [mg]
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed)
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed)
    AUC(0-25): area under the plasma concentration vs time curve from zero to 25 h p.a.
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed)
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed)
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 – 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only)
    AE,ur(0-25): amount of drug excreted via urine during the collection interval 0 – 25 h
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No
  • Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15
    date_rangeTime Frame:
    Multiple time points up to 6 weeks
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Number of patients with mutational status
    date_rangeTime Frame:
    Up to 3 years or longer if indicated
    enhanced_encryption
    Safety Issue:
    No
  • Tumor Response as measured by RECIST 1.1 criteria
    date_rangeTime Frame:
    Up to 3 years or longer if indicated
    enhanced_encryption
    Safety Issue:
    No

Trial design

A Phase 1 study of BAY80-6946 (phosphatidylinositol 3΄-kinase inhibitor) in combination with paclitaxel in subjects with advanced solid malignancy
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer products.